Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study

Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study

Abstract This phase II clinical trial aimed to evaluate the efficacy and safety of neoadjuvant long-course chemoradiotherapy combined with sintilimab in mismatch repair-proficient (pMMR)/microsatellite-stable (MSS) locally advanced rectal cancer (LARC) patients with a PD-L1 tumor proportion score (T...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhenlin Hou, Leen Liao, Weiwei Xiao, Qiaoqi Sui, Kai Han, Binyi Xiao, Yuan Li, Weijian Mei, Jiehai Yu, Zhigang Hong, Qichen Chen, Ruyue Song, Dandan Li, Xiaoshi Zhang, Qiaoxuan Wang, Zhizhong Pan, Wu Jiang, Peirong Ding
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-01018-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-025-01018-0

Similar Items